吉西他滨与多西紫杉醇联合顺铂在治疗非小细胞肺癌中的价值

目的探讨吉西他滨与多西紫杉醇联合顺铂在治疗非小细胞肺癌中的临床价值。方法选择35例患者使用吉西他滨联合顺铂治疗，并与35例使用多西紫杉醇联合顺铂的患者比较，连续2个治疗周期后观察患者的不良反应，并对所有患者电话随访1年，比较两组的临床疗效。结果吉西他滨组有效率为31．4％，多西紫杉醇组有效率为34-3％，两组有效率差异无统计学意义（P〉0．05）。吉西他滨组恶心呕吐的发生率显著高于多西紫杉醇组（P〈0．05）：多西紫杉醇组发生白细胞减少的概率显著高于吉西他滨组（P〈0．05）；两组发生血小板减少的概率均较高．但发生率之间差异无统计学意义（P〉0．05）；两组发生血红蛋白减少和肝肾功能受损的概率差异亦无统计学意义（P〉0．05）。结论吉西他滨与多西紫杉醇联合顺铂治疗非小细胞肺癌均有一定的临床效果，在使用吉西他滨治疗时主要注意患者的血小板调控以及预防恶心呕吐，使用多西紫杉醇治疗时则要注意患者的白细胞和血小板的数目。

The value of gemcitabine and docetaxel combined with cisplatin platinum in the treatment of non-small cell lung cancer

Objective To investigate the clinical value of gemcitabine and docetaxel combined with cisplatin platinum in the treatment of non-small cell lung cancer.Methods Thirty-five cases of patients were given gemcitabine and 35 cases of patients were given docetaxel combined with cisplatin,after two consecutive cycles of treatment,adverse reactions were observed,all patients were given telephone follow-up of 1 year,the two groups’ clinical efficacy were compared.Results Gemcitabine group effective rate was 31.4%,the docetaxel group was 34.3%,there was no significant difference between the two group(P > 0.05).Gemcitabine group nausea and vomiting rate was significantly higher than that of the docetaxel group(P < 0.05);docetaxel group leukopenia was significantly higher than that of the gemcitabine group(P < 0.05);thrombocytopenia incidence rate ratios was higher,but the incidence had no significant difference between the two groups(P > 0.05);the incidence of hemoglobin reduce and the rate of damage to the liver and kidney functions had no significant difference between the two groups(P > 0.05).Conclusion Gemcitabine and docetaxel combined with cisplatin platinum in the treatment of non-small cell lung cancer has a certain degree of clinical effect,the use of gemcitabine,the main attention to the patient’s platelet regulation and prevention of nausea and vomiting,the use of docetaxel will have to pay attention to the patient’s white blood cells and the number of platelets.